{"filing":{"accession_number":"0001193125-26-270384","cik":"0001980845","ticker":"ENGNW","company_name":"enGene Therapeutics Inc.","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"engn-20260613.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526270384/engn-20260613.htm"},"events":[{"id":10953,"run_id":9601,"accession_number":"0001193125-26-270384","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"enGene Therapeutics disclosed financial results for the three months ended April 30, 2026, including clinical and corporate updates, furnished via press release as Exhibit 99.1.","company_name":"enGene Therapeutics Inc.","ticker":"ENGNW","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7410,"accession_number":"0001193125-26-270384","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses financial results for the three months ended April 30, 2026, with a press release furnished as Exhibit 99.1. This is a standard quarterly earnings announcement under Item 2.02, which is material to investors as it provides periodic financial performance data essential to assessing the registrant's operational and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T13:15:24.302179+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7413,"accession_number":"0001193125-26-270384","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses financial results for Q2 ended April 30, 2026, via a press release attached as Exhibit 99.1. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the more typical Item 2.02, the substance is an earnings release with clinical and corporate updates. Quarterly financial results are material to investors assessing the registrant's operational performance and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T13:15:24.302179+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":10954,"run_id":9601,"accession_number":"0001193125-26-270384","anchor_item_number":"2.05","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The company announced a board-approved workforce reduction of approximately 50% with estimated restructuring costs of $5.7–$6.4 million in cash charges and $4.7–$5.0 million in non-cash stock-based compensation, plus $1.7 million in performance-based retention bonuses, designed to preserve cash while maintaining key strategic milestones.","company_name":"enGene Therapeutics Inc.","ticker":"ENGNW","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7411,"accession_number":"0001193125-26-270384","item_number":"2.05","item_title":"Costs Associated with Exit or Disposal Activities.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure centers on a board-approved workforce reduction of approximately 50% with estimated restructuring costs of $5.7–$6.4 million in cash charges plus $4.7–$5.0 million in non-cash stock-based compensation, along with performance-based retention bonuses of $1.7 million. While this is a material operational and financial event, it does not fit cleanly into the more specific event types (e.g., it is not an impairment charge, a covenant breach, or an executive departure per se, though it involves workforce reduction). The Item 2.05 classification and the nature of the restructuring—preserving cash while maintaining key strategic milestones—make this a material event that would affect a reasonable investor's assessment of the company's financial position and operational strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T13:15:24.302179+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":10955,"run_id":9601,"accession_number":"0001193125-26-270384","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Chief Medical Officer Dr. Hussein Sweiti resigned effective June 14, 2026, and Chief Financial Officer Ryan Daws separated effective July 15, 2026, representing material departures of two senior executives.","company_name":"enGene Therapeutics Inc.","ticker":"ENGNW","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7412,"accession_number":"0001193125-26-270384","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the resignation of Chief Medical Officer Dr. Hussein Sweiti effective June 14, 2026, and the separation of Chief Financial Officer Ryan Daws effective July 15, 2026. While the section also includes the appointment of Kathleen Richton as the new principal financial officer, the primary focus and most salient event is the departure of two senior executives, particularly the CMO and CFO roles. These departures are material to investors as they affect key leadership positions in a therapeutic company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T13:15:24.302179+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":10956,"run_id":9601,"accession_number":"0001193125-26-270384","anchor_item_number":"8.01","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Dr. William Grossman was appointed as Interim Chief Medical Officer effective June 15, 2026, and Kathleen Richton was appointed as principal financial officer, filling key C-suite positions following recent executive departures.","company_name":"enGene Therapeutics Inc.","ticker":"ENGNW","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7414,"accession_number":"0001193125-26-270384","item_number":"8.01","item_title":"Other Information.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Dr. William Grossman was appointed as Interim Chief Medical Officer effective June 15, 2026, representing a material executive appointment. While the section also discloses departures of three executives (Giguere, Nichols, Cheung) and cash retention agreements, the primary focus of Item 8.01 is the appointment of Grossman to a C-suite position, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T13:15:24.302179+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7410,"accession_number":"0001193125-26-270384","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses financial results for the three months ended April 30, 2026, with a press release furnished as Exhibit 99.1. This is a standard quarterly earnings announcement under Item 2.02, which is material to investors as it provides periodic financial performance data essential to assessing the registrant's operational and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T13:15:24.302179+00:00","company_name":"enGene Therapeutics Inc.","ticker":"ENGNW","filing_date":"2026-06-15"},{"id":7411,"accession_number":"0001193125-26-270384","item_number":"2.05","item_title":"Costs Associated with Exit or Disposal Activities.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure centers on a board-approved workforce reduction of approximately 50% with estimated restructuring costs of $5.7–$6.4 million in cash charges plus $4.7–$5.0 million in non-cash stock-based compensation, along with performance-based retention bonuses of $1.7 million. While this is a material operational and financial event, it does not fit cleanly into the more specific event types (e.g., it is not an impairment charge, a covenant breach, or an executive departure per se, though it involves workforce reduction). The Item 2.05 classification and the nature of the restructuring—preserving cash while maintaining key strategic milestones—make this a material event that would affect a reasonable investor's assessment of the company's financial position and operational strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T13:15:24.302179+00:00","company_name":"enGene Therapeutics Inc.","ticker":"ENGNW","filing_date":"2026-06-15"},{"id":7412,"accession_number":"0001193125-26-270384","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the resignation of Chief Medical Officer Dr. Hussein Sweiti effective June 14, 2026, and the separation of Chief Financial Officer Ryan Daws effective July 15, 2026. While the section also includes the appointment of Kathleen Richton as the new principal financial officer, the primary focus and most salient event is the departure of two senior executives, particularly the CMO and CFO roles. These departures are material to investors as they affect key leadership positions in a therapeutic company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T13:15:24.302179+00:00","company_name":"enGene Therapeutics Inc.","ticker":"ENGNW","filing_date":"2026-06-15"},{"id":7413,"accession_number":"0001193125-26-270384","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses financial results for Q2 ended April 30, 2026, via a press release attached as Exhibit 99.1. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the more typical Item 2.02, the substance is an earnings release with clinical and corporate updates. Quarterly financial results are material to investors assessing the registrant's operational performance and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T13:15:24.302179+00:00","company_name":"enGene Therapeutics Inc.","ticker":"ENGNW","filing_date":"2026-06-15"},{"id":7414,"accession_number":"0001193125-26-270384","item_number":"8.01","item_title":"Other Information.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Dr. William Grossman was appointed as Interim Chief Medical Officer effective June 15, 2026, representing a material executive appointment. While the section also discloses departures of three executives (Giguere, Nichols, Cheung) and cash retention agreements, the primary focus of Item 8.01 is the appointment of Grossman to a C-suite position, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T13:15:24.302179+00:00","company_name":"enGene Therapeutics Inc.","ticker":"ENGNW","filing_date":"2026-06-15"}]}